Zobrazeno 1 - 10
of 22
pro vyhledávání: '"J Michael, Hamilton"'
Publikováno v:
The Journal of Clinical Pharmacology. 49:30-38
A phase I study of AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, was carried out to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. Healthy male volunteers (N = 25) participated in this double-blind, rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0e78cc7dc43a76cfe9ad460339076e0
https://doi.org/10.1177/0091270008325149
https://doi.org/10.1177/0091270008325149
Autor:
J. Michael Hamilton, Andrew S. Elish, Julian Jenkins, Drew Provan, James B. Bussel, Bethan Psaila, Martin Lesser, Lemke K. Page
Publikováno v:
British Journal of Haematology. 138:245-248
A method for objective quantification of bleeding symptoms in immune thrombocytopenic purpura (ITP) has not been established. The ITP Bleeding Scale (IBLS) is a novel bleeding assessment system comprising 11 site-specific grades. Implementation of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ab53a88e5601340e902a4d0d6c2cb0
https://doi.org/10.1111/j.1365-2141.2007.06635.x
https://doi.org/10.1111/j.1365-2141.2007.06635.x
Autor:
Rebecca R. Thomas, J. Michael Hamilton, Elizabeth B. Agnew, Jean L. Grem, Geraldine Morrison, Chris H. Takimoto, Frank Grollman, Louise Grochow, Eva Szabo, Xiao Du Guo, Len Neckers, Richard H. Wilson
Publikováno v:
Journal of Clinical Oncology. 23:1885-1893
Purpose To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks. Patients and Methods Nineteen patients received 17-AAG over six dose levels (10 to 56 mg/m2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ec9755e546fd5b3041848629ccbde9
https://doi.org/10.1200/jco.2005.12.085
https://doi.org/10.1200/jco.2005.12.085
Autor:
Chris H. Takimoto, Dat Nguyen, Alice P. Chen, J. Michael Hamilton, Brian P. Monahan, Janet Pang, Mary G. Quinn, Yan Xu, Jean L. Grem, Anthony Rowedder, Bruce Keith, Nancy Harold, Geraldine Morrison
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:487-496
Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial.Gemcitabine alone was given in cycle 1 as a 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332cce0c9225697893274395cf2a66ee
https://doi.org/10.1007/s00280-003-0698-5
https://doi.org/10.1007/s00280-003-0698-5
Autor:
Philip M. Arlen, J. Michael Hamilton, James L. Gulley, Jeffrey Schlom, Anne Bastian, Seth M. Steinberg, Kwong Y. Tsang, William L. Dahut, Diane J. Poole, Dennis Panicali, Alice P. Chen
Publikováno v:
The Prostate. 53:109-117
BACKGROUND A Phase I trial of recombinant vaccinia prostate specific antigen (rV-PSA) in patients with advanced metastatic prostate cancer was conducted. This report describes 42 patients who were treated with up to three monthly vaccinations. METHOD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae6444d3774332151cc47ddfbac1bd52
https://doi.org/10.1002/pros.10130
https://doi.org/10.1002/pros.10130
Autor:
Osama E. Rahma, Malgorzata Wojtowicz, J. Michael Hamilton, Samir N. Khleif, Seth M. Steinberg, Sarah Bernstein, David J. Liewehr, Omar Dakheel
Publikováno v:
Journal of Translational Medicine
Background Mutant Ras oncogenes produce proteins that are unique to cancer cells and represent attractive targets for vaccine therapy. We have shown previously that vaccinating cancer patients with mutant ras peptides is feasible and capable of induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65002dc52773bc556054b12bfb2f1329
https://doi.org/10.1186/1479-5876-12-55
https://doi.org/10.1186/1479-5876-12-55
Publikováno v:
Leukemia & Lymphoma. 39:421-426
Varicella zoster (V-Z) infections are common among patients with hematological malignancies, particularly Hodgkin's disease (HD). The common denominator in both HD and V-Z infections is immunosuppression. Most of V-Z infections occur in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97eb61adc272d88c558a1c62739e6955
https://doi.org/10.3109/10428190009065843
https://doi.org/10.3109/10428190009065843
Autor:
Edward L. Kom, Richard M. Simon, Harry S. Wieand, T. Timothy Chen, Michael A. Friedman M D, Anne S. Lindblad, Bernard Fisher M.D, J. Michael Hamilton, M D Harold O. Douglass Jr, Stewart J. Anderson
Publikováno v:
Communications in Statistics - Theory and Methods. 27:1363-1378
A stochastic model wiuh exponential components is used to describe our data collected from a phase III cancer clinical trial. Criteria which guarantee that disease-free survival (DFS) can be used as a surrogate for overall survival are explored under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6661f0099fb6f6b1fdd43671c5c1953
https://doi.org/10.1080/03610929808832163
https://doi.org/10.1080/03610929808832163
Autor:
J. Michael Hamilton, Judy Kantor, Dennis Panicali, Kwong Y. Tsang, Scott I. Abrams, Jeffrey Schlom
Publikováno v:
Breast Cancer Research and Treatment. 38:27-39
The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f17876bcfea78770eac53d8151a576a
https://doi.org/10.1007/bf01803781
https://doi.org/10.1007/bf01803781
Autor:
Thomas D Brown, Timothy J OʼRourke, John G Kuhn, Johnny B Craig, Kathleen Havlin, Howard A Burris, John Cagnola, J Michael Hamilton, Gerald B Grindey, Winston G Satterlee, Daniel D Von Hoff
Publikováno v:
Anti-Cancer Drugs. 5:151-159
Sulofenur (LY186641), a diarylsulfonylurea, was evaluated clinically utilizing either a daily x 21 schedule or a daily x 5 (with 2 days off) for 3 weeks schedule. Eighteen patients with refractory solid tumors received 47 evaluable courses of sulofen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::546a59241c9dbe1fb051ad0c0642e950
https://doi.org/10.1097/00001813-199404000-00005
https://doi.org/10.1097/00001813-199404000-00005